Novo Nordisk hands shelved Parkinson’s cell therapy to Zuckerberg-backed Cellular Intelligence

Novo will take an equity stake in Cellular Intelligence and is in line for future milestone payments and royalties. The startup plans to apply its AI platform to STEM-PD, a stem-cell-derived treatment Novo discontinued last October. Novo Nordisk has handed over STEM-PD, an experimental stem-cell therapy for Parkinson’s disease, to Cellular Intelligence, an AI biotech […] This story continues at The Next Web